Compare BridgeBio Pharma Inc (BBIO) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Uber Technologies Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Uber Technologies Inc trades at $78.39 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 9.6× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | UBER | |
|---|---|---|
Market Cap | $16.61B | $159.38B |
Sector | Health | Industrials |
52-Week High | $90.17 | $100.10 |
52-Week Low | $47.29 | $65.94 |
Enterprise Value | $18.16B | $168.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Uber Technologies (UBER) is trading at $75.02, up 6.46% today, with strong technical momentum and bullish moving averages. The company shows robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023. Recent developments include expansion into autonomous vehicle partnerships and strategic workforce adjustments in HR roles.
Uber presents a compelling growth story with improving profitability and strong analyst support (81.67% buy rating). Key risks include execution challenges in autonomous vehicle deployment and competitive pressures in key markets like India. The consensus price target of $102.88 suggests significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
